ARA-290
From $32.00to $1170.00
For laboratory research use only. Not for human or animal use, consumption, diagnosis, treatment, or disease prevention.
This item is available only through approved account access.
Product Specifications
- Lot Number
- —
- Purity
- —
- Storage Temp
- 36°F to 46°F
For Research Use Only. Not for human or animal administration. Not intended to diagnose, treat, cure, or prevent any disease. Sold for laboratory research purposes only.
Documentation
Certificates of Analysis are supplied with each product lot where applicable.
Certificate of Analysis (COA)
Documentation will be available once product lots are received and tested.
All products currently listed on this site are for research purposes only.
COA Library
Published Certificates of Analysis for ARA-290. New deliveries are added as their batches are released.
No released COA for this strength yet
Reports appear here once a batch for this strength has been released.
Research Data
Chemical & Structural Identifiers
- Chemical Name (IUPAC)
- 5-Oxo-L-prolyl-L-glutamyl-L-glutaminyl-L-leucyl-L-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-L-serine
- Sequence
- pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH
- Physical Form
- Pure white to off-white lyophilized solid/powder.
- Synonyms
- ARA-290, Cibinetide, Helix B Surface Peptide (HBSP) Analog, Pyr-EPO(11-mer)
Handling & Stability
Storage. Store dry lyophilized powder desiccated at -20°C to -80°C, sealed under an inert gas matrix and protected from light.
Solubility. Soluble in sterile laboratory-grade deionized water (≥ 10 mg/mL), sterile Phosphate-Buffered Saline (PBS, pH 7.4, ≥ 5 mg/mL), or dilute aqueous buffers for in vitro assay application.
- Solution Stability & Handling: The N-terminal pyroglutamate residue provides stability against standard aminopeptidase degradation; avoid excessive aeration, high-shear vortexing, and repeated freeze-thaw cycles once dissolved in aqueous buffers.
Mechanism & Literature
Structural Engineering Focus: Synthetic 11-amino acid linear peptide designed from the aqueous-exposed face of erythropoietin (EPO) Helix B. Engineered specifically to selectively engage the heteromeric Innate Repair Receptor (IRR)—a complex formed by the Erythropoietin Receptor subunit and the common β receptor (EPOR/CD131 heterodimer).
Cellular Pathways Investigated: Does not bind to the classical (EPOR)2 homodimer and exhibits zero erythropoietic activity in cell culture assays. Studied in neuronal, Schwann cell, and macrophage cell lines (e.g., RAW 264.7) to analyze downstream inhibition of nuclear factor-κB (NF-κB) nuclear translocation and phosphorylation of cytoprotective Akt/GSK-3β signaling cascades.
References (2)
- Brines, M., et al. (2008). Nonerythropoietic, tissue-protective peptides derived from the surface of erythropoietin B-helix. Proceedings of the National Academy of Sciences (PNAS), 105(31), 10925–10930.
- Swartjes, M., et al. (2014). ARA 290, a peptide derived from erythropoietin, activates the innate repair receptor and attenuates inflammatory signaling in vitro. Molecular Medicine, 20(1), 619–626.
Technical Laboratory FAQs
How does ARA-290 differ functionally from full-length erythropoietin (EPO) in vitro?
ARA-290 selectively targets the heteromeric EPOR/CD131 Innate Repair Receptor (IRR) without binding the classical homodimeric (EPOR)2 receptor, completely uncoupling tissue-protective cellular signaling from erythropoiesis.
For Research Use Only. Not for human or animal administration. Not intended to diagnose, treat, cure, or prevent any disease. Sold for laboratory research purposes only.